Stockscreener 앱 받기
14.34
0.03%
0.010
Amicus Therapeutics Inc 주식(FOLD)의 최신 뉴스
Amicus Therapeutics Buyout Advances As Valuation Gap Draws Investor Focus - Yahoo Finance
Bradley Campbell Sells 22,500 Shares of Amicus Therapeutics (NASDAQ:FOLD) Stock - MarketBeat
Insider Sell: Bradley Campbell Sells 22,500 Shares of Amicus The - GuruFocus
FOLD SEC FilingsAmicus Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
FDA’s rare disease toolbox not fully used - bioworld.com
JPMorgan Chase & Co. Has $16.68 Million Stock Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Amicus Therapeutics shareholders approve acquisition by BioMarin Pharmaceutical - Investing.com
Amicus Stockholders Approve BioMarin Acquisition at Special Meeting - TipRanks
Shareholders back Amicus (NASDAQ: FOLD) sale to BioMarin Pharmaceutical - Stock Titan
Amicus Therapeutics, Inc. (FOLD) Stock Analysis: Navigating the Biotech Sector with a 23.7% Revenue Growth - DirectorsTalk Interviews
Bradley Campbell sells 75,000 FOLD shares under 10b5-1 plan (FOLD) - Stock Titan
Vanguard Group Inc. Buys 126,441 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
FOLD Stock Price, Quote & Chart | AMICUS THERAPEUTICS INC (NASDAQ:FOLD) - ChartMill
William Blair Investment Management LLC Buys 1,107,083 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
Fox Run Management L.L.C. Takes $553,000 Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Primecap Management Co. CA Sells 128,200 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
FOLD Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Amicus Therapeutics Experiences Revision in Stock Score Amid Mixed Financial Performance - Markets Mojo
BIOMARIN PHARMACEUTICAL INC SEC 10-K Report - TradingView
BioMarin Deal Reshapes Amicus Therapeutics Outlook For Growth And Portfolio - simplywall.st
Amicus Therapeutics, Inc. (FOLD) Stock Analysis: Navigating Growth in Rare Diseases with Strong Revenue Momentum - DirectorsTalk Interviews
BioMarin Amicus Deal Shifts Rare Disease Portfolio And Valuation Focus - Yahoo Finance
Precision Trading with Amicus Therapeutics Inc. (FOLD) Risk Zones - Stock Traders Daily
Assessing Amicus Therapeutics (FOLD) Valuation After A Strong 3 Month Share Price Rally - simplywall.st
BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results - The AI Journal
Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues - Finviz
Amicus Therapeutics: Q4 Earnings Snapshot - kare11.com
Amicus Therapeutics: Fourth Quarter Financial Results Overview - Bitget
Amicus Therapeutics Q4 Highlights: Revenue Growth Amid Losses - Intellectia AI
Amicus Therapeutics Q4 Profit Print Tests Bullish Profitability Narratives - Sahm
Will Amicus Therapeutics Inc. benefit from sector rotationEarnings Overview Report & Daily Entry Point Alerts - mfd.ru
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates - The Manila Times
Decoding Amicus Therapeutics Inc (FOLD): A Strategic SWOT Insigh - GuruFocus
Amicus Therapeutics (NASDAQ:FOLD) Announces Quarterly Earnings Results - MarketBeat
Amicus Therapeutics (FOLD) Beats Q4 Revenue Expectations - GuruFocus
AMICUS THERAPEUTICS, INC. SEC 10-K Report - TradingView
Is Amicus Therapeutics Inc.’s ROIC above industry averageWeekly Trading Summary & Intraday High Probability Setup Alerts - mfd.ru
TD Cowen cautious on Amicus Therapeutics (FOLD) despite positive 2025 revenue projections - MSN
Amicus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Halper Sadeh LLC is Investigating Whether RAPT, CTGO, TBN, FOLD are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
TD Cowen Cautious on Amicus Therapeutics (FOLD) Despite Positive 2025 Revenue Projections - Finviz
Amicus earnings on deck as $4.8B BioMarin deal awaits vote - Investing.com India
Aug Levels: Will Amicus Therapeutics Inc benefit from geopolitical trendsWeekly Trend Report & Smart Investment Allocation Tips - baoquankhu1.vn
Principal Financial Group Inc. Has $2.08 Million Stock Holdings in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Amicus Therapeutics, Inc. (FOLD) Stock Analysis: Navigating Current Valuations with Strong Revenue Growth - DirectorsTalk Interviews
BioMarin to buy rare disease drugmaker Amicus Therapeutics for $4.8B - MSN
What to Expect From These Drug/Biotech Players This Earnings Season? - TradingView
BioMarin Debt Deal And VOXZOGO Approval Recast Rare Disease Outlook - Yahoo Finance
Can Amicus Therapeutics Inc. expand its profit marginsPortfolio Gains Summary & Smart Swing Trading Techniques - mfd.ru
BioMarin Pharmaceutical, Amicus Therapeutics deal gets early termination from US FTC - MLex
Why Amicus Therapeutics Inc. stock is in analyst buy zoneJuly 2025 Final Week & Trade Opportunity Analysis - mfd.ru
Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings? - Finviz
Amicus Therapeutics (FOLD) to Release Earnings on Wednesday - MarketBeat
Jefferies Downgrades Amicus Therapeutics, Inc. (FOLD) to Buy And Lowers Price Target Amid Takeover Developments - MSN
4.07%
0.71%
자본화:
|
볼륨(24시간):